Biotech VCs Scramble as 'Old Exon Science' Gains New Traction, PhRMA CEO Search Looms

A quiet but significant shift is unsettling the venture capital playbook in biotech. The focus is turning back to foundational 'exon science'—a well-established area of genetics—which is suddenly attracting fresh capital and strategic interest. This pivot signals a potential recalibration of risk and opportunity, as investors seek value in proven biological mechanisms over purely novel, and often unproven, technological platforms.

The movement raises immediate questions about which companies and research pipelines will benefit from this renewed focus. Concurrently, the industry faces a major leadership vacuum with the ongoing search for the next CEO of PhRMA, the powerful pharmaceutical industry lobbying group. The selection will occur against this backdrop of financial repositioning, placing the new leader at the nexus of scientific, investment, and political pressures.

This convergence of old science gaining new traction and high-stakes executive search points to a sector in a state of strategic flux. The decisions made by VCs on where to deploy capital, coupled with the direction set by PhRMA's future leadership, will shape the competitive landscape, influence regulatory engagement, and determine which therapeutic areas receive the momentum needed to advance from lab to clinic.